文献速递血脂与心血管预防

阿利西尤单抗治疗成人纯合子家族性高胆固醇血症的疗效与安全性:ODYSSEY HoFH试验

Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

ODYSSEY HoFH是一项随机、双盲、安慰剂对照、平行组3期研究,评估阿利西尤单抗150 mg每2周一次在成人纯合子家族性高胆固醇血症患者中的疗效与安全性。共69例患者按2:1随机分配,第12周时阿利西尤单抗组LDL-C较基线降低26.9%,安慰剂组升高8.6%,组间最小二乘均值差异为-35.6%(p<0.0001)。阿利西尤单抗总体耐受良好,安全性特征与安慰剂相当。

要点

  • 阿利西尤单抗150 mg每2周一次可使HoFH患者第12周LDL-C较基线降低26.9%。
  • 安慰剂校正后LDL-C降幅为-35.6%(p<0.0001)。
  • 载脂蛋白B、非高密度脂蛋白胆固醇、总胆固醇和脂蛋白(a)均显著降低。

核心结论

  • 在迄今最大的HoFH患者随机对照干预试验中,阿利西尤单抗第12周显著降低LDL-C,且耐受性良好。

研究设计与样本

  • 随机、双盲、安慰剂对照、平行组3期研究,评估阿利西尤单抗150 mg每2周一次,69例患者按2:1随机分配。

主要发现

  • 第12周LDL-C较基线变化的最小二乘均值组间差异为-35.6%(阿利西尤单抗-26.9% vs 安慰剂8.6%,p<0.0001)。
  • 载脂蛋白B降低29.8%,非高密度脂蛋白胆固醇降低32.9%,总胆固醇降低26.5%,脂蛋白(a)降低28.4%(均p<0.0001)。
  • 双盲治疗期间未报告因治疗中出现的不良事件导致的严重不良事件、永久停药或死亡。

关键数值与推荐

  • 主要终点为治疗12周后LDL-C较基线百分比变化相较于安慰剂的差异。
  • 基线平均LDL-C:安慰剂组259.6 mg/dl,阿利西尤单抗组295.0 mg/dl。
  • 基线背景降脂治疗包括67例使用他汀(59例高强度他汀)、50例使用依折麦布、10例使用洛美他派、10例接受血浆置换。

临床怎么用

  • 对于接受常规降脂治疗的成人HoFH患者,可考虑加用阿利西尤单抗150 mg每2周一次以进一步降低LDL-C。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is characterized by extremely elevated low-density lipoprotein-cholesterol (LDL-C) levels and early onset atherosclerotic cardiovascular disease despite treatment with conventional lipid-lowering treatment. OBJECTIVES: This study was designed to assess LDL-C reduction with the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in adult patients with HoFH. METHODS: This randomized, double-blind, placebo-controlled, parallel-group, phase 3 study evaluated efficacy and safety of alirocumab 150 mg every 2 weeks. The primary endpoint was percent reduction from baseline in LDL-C versus placebo after 12 weeks of treatment. RESULTS: Patients (N = 69) were randomized 2:1 to alirocumab or placebo. At baseline, background lipid-lowering treatment included 67 patients receiving statin (59 patients on high-intensity statin); 50 patients on ezetimibe; 10 patients on lomitapide; and 10 patients undergoing apheresis. Mean baseline LDL-C was 259.6 mg/dl in the placebo group and 295.0 mg/dl in the alirocumab group. At week 12, the least squares mean difference in LDL-C percent change from baseline was -35.6% (alirocumab [-26.9%] vs. placebo [8.6%]; p < 0.0001). Reductions (least squares mean difference) in other atherogenic lipids at week 12 were: apolipoprotein B, -29.8%; non-high-density lipoprotein cholesterol, -32.9%; total cholesterol, -26.5%; and lipoprotein(a), -28.4% (all p < 0.0001). No serious adverse events, permanent treatment discontinuations, or deaths due to treatment-emergent adverse events were reported during the double-blind treatment period. CONCLUSIONS: In the largest randomized controlled interventional trial in HoFH patients to date, alirocumab resulted in significant and clinically meaningful reductions in LDL-C at week 12. Alirocumab was generally well tolerated, with a safety profile comparable to that of placebo. (Study in Participants With Homozygous Familial Hypercholesterolemia [HoFH] [ODYSSEY HoFH] NCT03156621.).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Blom DJ, Harada-Shiba M, Rubba P, et al. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial. J Am Coll Cardiol. 2020. PMID: 32646561. doi:10.1016/j.jacc.2020.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。